Drug Trial Radar · NCT05537038
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Apr 18, 2023
Primary completion
Jun 6, 2025
Study completion Dec 8, 2025
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Sep 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule.
Conditions
- Tuberculosis
Interventions
BNT164a1Biological
Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
BNT164b1Biological
Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each doseTime frame: Up to 7 days after each dose
- Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain and joint pain, chills, and fever) up to 7 days after each doseTime frame: Up to 7 days after each dose
- Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each doseTime frame: From Day 1 until Day 197
- Proportion of participants with at least one AE occurring from Dose 1 to 28 days post-Dose 3Time frame: From Day 1 until Day 197
- Proportion of participants with at least one serious adverse event (SAE) or medically attended adverse event (MAAE) occurring from Dose 1 up to 168 days post-Dose 3Time frame: From Day 1 until Day 337
- Number of AEs from Dose 1 to 28 days post-Dose 3Time frame: From Day 1 until Day 197
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
emovis GmbH
Berlin, Germany
CRS Clinical Research Services Berlin GmbH
Berlin, Germany
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.